Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: Evidence for a difference in antithrombotic action

British Journal of Haematology

Volumn 101, Issue 4, 1998, Pages 638-646

  Hansen, John Bjarne ^a   Sandset, Per Morten ^b   Huseby, Kirsten Raanaas ^a   Huseby, Nils Erik ^a   Bendz, Bjørn ^b   Østergaard, Per ^c   Nordøy, Arne ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Anticoagulant therapy; Low molecular weight heparin; Tissue factor; Tissue factor pathway inhibitor; Unfractionated heparin

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THROMBOSIS;

EID: 0031802855     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00770.x     Document Type: Article

References (44)

1. Abumiya, T., Enjyoji, K., Kokawa, T., Kamikabo, Y. & Kato, H. (1995) An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. Journal of Biochemistry, 118, 178-182.
2. Almus, F.E., Rao, L.V.M. & Rapaport, S.I. (1993) Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arteriosclerosis and Thrombosis, 13, 105-111.
3. Anderson, S., Cohen, A.T., Melissari, E., Scully, M.S. & Kakkar, V.V. (1995) Loss of heparin-releasable tissue factor pathway inhibitor in patients undergoing PTCA. Thrombosis and Haemostasis, 73, 328-329.
4. Bajaj, M.S., Kuppuswamy, M.N., Saito, H., Spitzer, S.G. & Bajaj, S.P. (1990) Cultured normal hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proceedings of the National Academy of Sciences of the United States of America, 87, 8869-8873.
5. Bara, L., Billaud, E., Gramond, G., Kher, A. & Samama, M. (1985) Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thrombosis Research, 39, 631-636.
6. Bara, L., Bloch, M.F., Zitoun, D., Samama, M., Collinon, F., Frydman, A., Uzban, A. & Bouthier, J. (1993) Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thrombosis Research, 69, 443-452.
7. Bergqvist, D., Benoni, G., Björgell, O., Fredin, H., Hedlundh, U., Nicolas, S., Nilsson, P. & Nylander, G. (1996) Low-molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. New England Journal of Medicine, 335, 696-700.
8. Broze, G.J., Jr, Warren, L.A., Novotny, W.F., Higuchi, D.A., Girard, J.J. & Miletich, J.P. (1988) The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood, 71, 335-343.
9. Cohen, M., Demers, C., Gurfinkel, E.P., Turpie, A.G.G., Fromell, G.J., Goodman, S., Langer, A., Califf, R.M., Fox, K.A.A., Premmereur, J. & Bigonzi, F. (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. New England Journal of Medicine, 337, 447-452.
10. Erhardsen, E., Ezban, M., Madsen, M.T., Diness, V., Glazer, S., Hedner, U. & Nordfang, O. (1995) Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagulation and Fibrinolysis, 5, 388-395.
11. Girard, T.J., Warren, L.A., Novotny, W.F., Likert, K.M., Brown, S.G., Miletich, J.P. & Broze, G.J., Jr (1989) Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature, 338, 518-520.
12. Grabowski, E.F., Zuckerman, D.B. & Nemerson, Y. (1993) The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions. Blood, 81, 3265-3270.
13. Granger, C.B., Miller, J.M., Bovill, E.G., Gruber, A., Tracy, R.P., Krucoff, M.W., Green, C., Berrios, E., Harrington, R.A., Ohman, E.M. & Califf, R.M. (1995) Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary' syndromes. Circulation, 91, 1929-1935.
14. Gurfinkel, E.P., Manos, E.J., Mejail, R.I., Cerda, M.A., Duronto, E.A., Garcia, C.N., Daroca, A.M. & Mautner, B. (1995) Low molecular weight heparin versus heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiologists, 26, 313-318.
15. Hansen, J.B., Huseby, K.R., Huseby, N.B., Ezban, M. & Nordøy, A. (1997) Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thrombosis Research, 85, 413-425.
16. Hansen, J.B., Huseby, K.R., Huseby, N.E., Sandset, P.M., Hansen, T.A. & Nordoy, A. (1995) Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arteriosclerosis, Thrombosis and Vascular Biology, 15, 879-885.
17. Hansen, J.B., Sandset, P.M., Huseby, K.R., Huseby, N.E. & Nordøy, A. (1996) Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thrombosis and Haemostasia, 76, 705-709.
18. Harenberg, J., Siegele, M., Dempfle, C.E., Stehle, G. & Heene, D.L. (1993) Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thrombosis and Haemostasis, 70, 942-945.
19. Hemker, H.C. & Beguin, S. (1990) Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma. Haemostasis, 20, (Suppl. 1), 81-92.
20. Hirsh, J. (1996) Comparison of the relative efficacy and safely of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Haemostasis, 26, (Suppl. 4), 189-198.
21. Hjort, P.F. (1957) Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scandinavian Journal of Clinical and Laboratory Investigation, 9, (Suppl. 27), 1-173.
22. Hommes, D.W., Bara, A., Mazzolai, L., Büller, H.R. & ten Cate, J.W. (1992) Subcutaneous treatment compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Annals of Internal Medicine, 116, 279-284.
23. Hoppensteadt, D.A., Walenga, J.M., Fasanella, A., Jeske, W. & Fareed, J. (1995) TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and low molecular weight heparin. Thrombosis Research, 77, 175-185.
24. Hull, R.D., Raskob, G.E., Hirsch, J., Jay, R.M., Leclerc, J.R., Geerts, W.H., Rosenbloom, D., Sackitt, D.L., Anderson, C., Harrison, L. & Gent, M. (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New England Journal of Medicine, 315, 1109-1114.
25. Hull, R.D., Raskob, G.E., Pineo, G.F., Green, D., Trowbridge, A.A., Elliot, G., Lerner, R.G., Hall, J., Sparling, T., Bretelli, H.R., Norton, J., Carter, C.J., George, R., Merli, G., Ward, J., May, O.W., Rosenbloom, D. & Brant, R. (1992) Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine, 326, 975-982.
26. Kasper, C.K., Aledort, M.L., Counts, R.B., Edson, J.R., Fratantoni, J., Green, D., Hampton, J.W., Hilgartner, M. W., Lazerson, J., Levine, P.H., McMillan, C.W., Pool, J.G., Shapiro, S.S., Shulman, N.R. & van Eys, J. (1975) A more uniform measurement of factor VIII inhibitors. Thrombosis et Diathesis Haemorrhagica, 34, 869-872.
27. Lindahl, A.K., Abildgaard, U. & Staalesen, R. (1991) The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thrombosis Research, 64, 155-168.
28. Lindahl, A.K., Sandset, P.M. & Abildgaard, U. (1992) The present status of tissue factor pathway inhibitor. Blood Coagulation and Fibrinolysis, 3, 439-449.
29. Merlini, P.A., Bauer, K.A., Oltrona, L., Ardissino, H., Cattaneo, M., Belli, C., Mannucci, P.M. & Rosenberg, R.D. (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation, 90, 61-68.
30. Neri Serneri, G.G., Gensini, G.F., Poggesi, L., Trotta, F., Modesti, P.A., Boddi, M., Ieri, A., Margheri, M., Casolo, G.C., Bini, M., Rostagno, C., Carnovali, M. & Abbate, R. (1990) Effect of heparin, aspirin, or alteplase in the reduction of myocardial ischaemia in refractory unstable angina. Lancet, 335, 615-618.
31. Noble, S., Peters, D.H. & Goa, K.L. (1995) Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs, 49, 388-410.
32. Nordfang, O., Bjørn, S.E., Valentin, S., Nielsen, L.S., Wildgoose, P., Beck, T.C. & Hedner, U. (1991) The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry, 30, 10371-10376.
33. Novotny, W.F., Palmier, M., Wun, T.C., Broze, G.J., Jr & Miletich, J.P. (1991) Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood, 78, 594-400.
34. Østergaard, P.B., Beck, T.C., Ørsted, H., Svendsen, A., Nordfang, O., Sandset, P.M. & Hansen, J.B. (1997) An enzyme linked immunosorption assay for tissue factor pathway inhibitor. Thrombosis Research, 87, 447-459.
35. Samama, M.M., Bara, L. & Gerotziafas, G.T. (1994) Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis, 24, 105-117.
36. Sandset, P.M., Abildgaard, U. & Larsen, M.L. (1988) Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thrombosis Research, 50, 803-813.
37. Sandset, P.M., Warn-Cramer, B.J., Maki, S.L. & Rapaport, S.I. (1991a) Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Schwatzman reaction. Blood, 78, 1496-1502.
38. Sandset, P.M., Warn-Cramer, B.J., Rao, L.V.M., Maki, S.L. & Rapaport, S.I. (1991b) Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiological role for EPI as a natural anticoagulant. Proceedings of the National Academy of Sciences of the United States of America, 88, 708-712.
39. SAS (1987) SAS/STAT Guide for Personal Computers, Version 6. SAS Institute, Cary, N.C.
40. Theroux, P., Waters, D., Lam, J., Juneau, M. & McCans, J. (1992) Reactivation of unstable angina after discontinuation of heparin. New England Journal of Medicine, 327, 141-145.
41. Valentin, S., Larnkjær, A., Østergaard, P., Nielsen, J.I. & Nordfang, O. (1994) Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thrombosis Research, 74, 173-184.
42. Valentin, S., Østergaard, P., Kristensen, H. & Norfang, O. (1992) Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin. Blood Coagulation and Fibrinolysis, 3, 221-222.
43. Warn-Cramer, B.J., Rao, L.V.M., Maki, S.L. & Rapaport, S.I. (1988) Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thrombosis and Haemostasis, 60, 453-456.
44. Wesselschmidt, R., Likert, K.M., Girard, T.J., Wun, T.C. & Broze, G.J., Jr (1992) Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood, 79, 2004-2010.